ID   IDS_HUMAN               Reviewed;         550 AA.
AC   P22304; D3DWT4; Q14604; Q9BRM3;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Iduronate 2-sulfatase;
DE            EC=3.1.6.13;
DE   AltName: Full=Alpha-L-iduronate sulfate sulfatase;
DE            Short=Idursulfase;
DE   Contains:
DE     RecName: Full=Iduronate 2-sulfatase 42 kDa chain;
DE   Contains:
DE     RecName: Full=Iduronate 2-sulfatase 14 kDa chain;
DE   Flags: Precursor;
GN   Name=IDS; Synonyms=SIDS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 34-58
RP   AND 456-473.
RC   TISSUE=Endothelial cell;
RX   PubMed=2122463; DOI=10.1073/pnas.87.21.8531;
RA   Wilson P.J., Morris C.P., Anson D.S., Occhiodoro T., Bielicki J.,
RA   Clements P.R., Hopwood J.J.;
RT   "Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and
RT   analysis of patient DNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8531-8535(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8244397; DOI=10.1006/geno.1993.1406;
RA   Wilson P.J., Meaney C.A., Hopwood J.J., Morris C.P.;
RT   "Sequence of the human iduronate 2-sulfatase (IDS) gene.";
RL   Genomics 17:773-775(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8717057; DOI=10.1101/gr.5.1.71;
RA   Timms K.M., Lu F., Shen Y., Pierson C.A., Muzny D.M., Gu Y.,
RA   Nelson D.L., Gibbs R.A.;
RT   "130 kb of DNA sequence reveals two new genes and a regional
RT   duplication distal to the human iduronate-2-sulfate sulfatase locus.";
RL   Genome Res. 5:71-78(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Lymphocyte;
RX   PubMed=8530090; DOI=10.1006/geno.1995.1249;
RA   Malmgren H., Carlberg B.M., Pettersson U., Bondeson M.L.;
RT   "Identification of an alternative transcript from the human iduronate-
RT   2-sulfatase (IDS) gene.";
RL   Genomics 29:291-293(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-398.
RX   PubMed=8490623; DOI=10.1093/hmg/2.1.5;
RA   Flomen R.H., Green E.P., Green P.M., Bentley D.R., Giannelli F.;
RT   "Determination of the organisation of coding sequences within the
RT   iduronate sulphate sulphatase (IDS) gene.";
RL   Hum. Mol. Genet. 2:5-10(1993).
RN   [9]
RP   REVIEW ON MPS2 VARIANTS.
RX   PubMed=8111411; DOI=10.1002/humu.1380020603;
RA   Hopwood J.J., Bunge S., Morris C.P., Wilson P.J., Steglich C.,
RA   Beck M., Schwinger E., Gal A.;
RT   "Molecular basis of mucopolysaccharidosis type II: mutations in the
RT   iduronate-2-sulphatase gene.";
RL   Hum. Mutat. 2:435-442(1993).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-115.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   VARIANTS MPS2 ARG-135 AND GLY-422.
RX   PubMed=1303211; DOI=10.1093/hmg/1.5.335;
RA   Bunge S., Steglich C., Beck M., Rosenkranz W., Schwinger E.,
RA   Hopwood J.J., Gal A.;
RT   "Mutation analysis of the iduronate-2-sulfatase gene in patients with
RT   mucopolysaccharidosis type II (Hunter syndrome).";
RL   Hum. Mol. Genet. 1:335-339(1992).
RN   [12]
RP   VARIANT MPS2 TRP-468.
RX   PubMed=1284597; DOI=10.1093/hmg/1.9.755;
RA   Crotti P.L., Bunge S., Anderson R.A., Whitley C.B.;
RT   "Mutation R468W of the iduronate-2-sulfatase gene in mild Hunter
RT   syndrome (mucopolysaccharidosis type II) confirmed by in vitro
RT   mutagenesis and expression.";
RL   Hum. Mol. Genet. 1:755-757(1992).
RN   [13]
RP   VARIANTS MPS2 ARG-86; ASP-94; ARG-120; PRO-221 AND GLY-422.
RX   PubMed=8281149; DOI=10.1093/hmg/2.11.1871;
RA   Bunge S., Steglich C., Zuther C., Beck M., Morris C.P., Schwinger E.,
RA   Schinzel A., Hopwood J.J., Gal A.;
RT   "Iduronate-2-sulfatase gene mutations in 16 patients with
RT   mucopolysaccharidosis type II (Hunter syndrome).";
RL   Hum. Mol. Genet. 2:1871-1875(1993).
RN   [14]
RP   VARIANTS MPS2 GLU-68; HIS-293; GLY-478 AND ARG-485.
RX   PubMed=7981716; DOI=10.1002/humu.1380040206;
RA   Schroeder W., Wulff K., Wehnert M., Seidlitz G., Herrmann F.H.;
RT   "Mutations of the iduronate-2-sulfatase (IDS) gene in patients with
RT   Hunter syndrome (mucopolysaccharidosis II).";
RL   Hum. Mutat. 4:128-131(1994).
RN   [15]
RP   VARIANT MPS2 PRO-410.
RX   PubMed=7866405; DOI=10.1002/humu.1380040406;
RA   Ben-Simon-Schiff E., Bach G., Hopwood J.J., Abeliovich D.;
RT   "Mutation analysis of Jewish Hunter patients in Israel.";
RL   Hum. Mutat. 4:263-270(1994).
RN   [16]
RP   VARIANTS MPS2 TRP-132; TYR-229; ARG-358; HIS-469 AND CYS-523.
RX   PubMed=7887413;
RA   Jonsson J.J., Aronovich E.L., Braun S.E., Whitley C.B.;
RT   "Molecular diagnosis of mucopolysaccharidosis type II (Hunter
RT   syndrome) by automated sequencing and computer-assisted
RT   interpretation: toward mutation mapping of the iduronate-2-sulfatase
RT   gene.";
RL   Am. J. Hum. Genet. 56:597-607(1995).
RN   [17]
RP   VARIANTS MPS2 LEU-86; ASN-87; PRO-92; ASN-135; CYS-345 AND TRP-468.
RX   PubMed=7728156; DOI=10.1002/humu.1380050114;
RA   Popowska E., Rathmann M., Tylki-Szymanska A., Bunge S., Steglich C.,
RA   Schwinger E., Gal A.;
RT   "Mutations of the iduronate-2-sulfatase gene in 12 Polish patients
RT   with mucopolysaccharidosis type II (Hunter syndrome).";
RL   Hum. Mutat. 5:97-100(1995).
RN   [18]
RP   VARIANTS MPS2 PRO-48; SER-117 DEL; LEU-333; ARG-337; LEU-468 AND
RP   GLN-468.
RX   PubMed=7581397; DOI=10.1002/humu.1380060206;
RA   Sukegawa K., Tomatsu S., Fukao T., Iwata H., Song X.-Q., Yamada Y.,
RA   Fukuda S., Isogai K., Orii T.;
RT   "Mucopolysaccharidosis type II (Hunter disease): identification and
RT   characterization of eight point mutations in the iduronate-2-sulfatase
RT   gene in Japanese patients.";
RL   Hum. Mutat. 6:136-143(1995).
RN   [19]
RP   VARIANT MPS2 VAL-346.
RX   PubMed=7599640; DOI=10.1002/humu.1380050314;
RA   Li P., Huffman P., Thompson J.N.;
RT   "Mutations of the iduronate-2-sulfatase gene on a T146T background in
RT   three patients with Hunter syndrome.";
RL   Hum. Mutat. 5:272-274(1995).
RN   [20]
RP   VARIANTS MPS2 ASP-63; THR-85; GLN-86; CYS-88; HIS-88; CYS-108; SER-117
RP   DEL; VAL-125; ARG-134; PHE-184; ASN-252; LEU-333; ILE-347; ARG-403 AND
RP   GLN-468.
RX   PubMed=8940265;
RA   Rathmann M., Bunge S., Beck M., Kresse H., Tylki-Szymanska A., Gal A.;
RT   "Mucopolysaccharidosis type II (Hunter syndrome): mutation 'hot spots'
RT   in the iduronate-2-sulfatase gene.";
RL   Am. J. Hum. Genet. 59:1202-1209(1996).
RN   [21]
RP   VARIANTS MPS2 LEU-333 AND ASP-346.
RX   PubMed=8566953; DOI=10.1007/BF02265265;
RA   Olsen T.C., Eiken H.G., Knappskog P.M., Kase B.F., Mansson J.-E.,
RA   Boman H., Apold J.;
RT   "Mutations in the iduronate-2-sulfatase gene in five Norwegians with
RT   Hunter syndrome.";
RL   Hum. Genet. 97:198-203(1996).
RN   [22]
RP   VARIANTS MPS2 ASP-63; ARG-86; GLY-95; PRO-205; TRP-468 AND GLN-468.
RX   PubMed=8664909;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<76::AID-HUMU14>3.0.CO;2-P;
RA   Goldenfum S.L., Young E., Michelakakis H., Tsagarakis S.,
RA   Winchester B.;
RT   "Mutation analysis in 20 patients with Hunter disease.";
RL   Hum. Mutat. 7:76-78(1996).
RN   [23]
RP   VARIANTS MPS2 LEU-333 AND GLY-334.
RX   PubMed=8830188; DOI=10.1007/BF01799358;
RA   Li P., Thompson J.N.;
RT   "Detection of four novel mutations in the iduronate-2-sulphatase gene
RT   by single-strand conformation polymorphism analysis of genomic
RT   amplicons.";
RL   J. Inherit. Metab. Dis. 19:93-94(1996).
RN   [24]
RP   VARIANTS MPS2 ASP-63; THR-347; GLN-468 AND LEU-468.
RX   PubMed=9222763;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<71::AID-HUMU10>3.0.CO;2-X;
RA   Villani G.R.D., Balzano N., Grosso M., Salvadore F., Izzo P.,
RA   di Natale P.;
RT   "Mucopolysaccharidosis type II: identification of six novel mutations
RT   in Italian patients.";
RL   Hum. Mutat. 10:71-75(1997).
RN   [25]
RP   VARIANT MPS2 GLN-468.
RX   PubMed=9375851;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:5<361::AID-HUMU5>3.3.CO;2-I;
RA   Sukegawa K., Song X.-Q., Masuno M., Fukao T., Shimozawa N., Fukuda S.,
RA   Isogai K., Nishio H., Matsuo M., Tomatsu S., Kondo N., Orii T.;
RT   "Hunter disease in a girl caused by R468Q mutation in the iduronate-2-
RT   sulfatase gene and skewed inactivation of the X chromosome carrying
RT   the normal allele.";
RL   Hum. Mutat. 10:361-367(1997).
RN   [26]
RP   VARIANTS MPS2 PHE-73; THR-118 DEL; HIS-121; TRP-132; ARG-336; LYS-341;
RP   GLN-347; TRP-468; GLN-468; LYS-521 AND VAL-521.
RX   PubMed=9266380; DOI=10.1023/A:1005335624386;
RA   Lissens W., Seneca S., Liebaers I.;
RT   "Molecular analysis in 23 Hunter disease families.";
RL   J. Inherit. Metab. Dis. 20:453-456(1997).
RN   [27]
RP   VARIANTS MPS2 ASN-45; TYR-115; LEU-228; ARG-266; LYS-434; LYS-485 AND
RP   CYS-502.
RX   PubMed=9875019; DOI=10.1136/adc.79.3.237;
RA   Vafiadaki E., Cooper A., Heptinstall L.E., Hatton C.E., Thornley M.,
RA   Wraith J.E.;
RT   "Mutation analysis in 57 unrelated patients with MPS II.";
RL   Arch. Dis. Child. 79:237-241(1998).
RN   [28]
RP   VARIANTS MPS2 ASN-71; SER-85; THR-85; LEU-86; GLY-88; HIS-88; PHE-89;
RP   SER-108; SER-117 DEL; ILE-118; ARG-121; ASP-138; HIS-148; ARG-229;
RP   LEU-333; ASN-334; ARG-335; GLU-336; ARG-339; ARG-403; LEU-467;
RP   GLN-468; TRP-468; ARG-480; GLN-480; LEU-480 AND SER-490.
RX   PubMed=9660053;
RA   Froissart R., Maire I., Millat G., Cudry S., Birot A.-M., Bonnet V.,
RA   Bouton O., Bozon D.;
RT   "Identification of iduronate sulfatase gene alterations in 70
RT   unrelated Hunter patients.";
RL   Clin. Genet. 53:362-368(1998).
RN   [29]
RP   VARIANTS MPS2 ASP-54; ASP-63; GLU-79; CYS-88; LEU-88; HIS-88; ARG-102;
RP   PRO-159; SER-196; GLY-198; GLU-224; LEU-333; ASP-340; TYR-432;
RP   GLN-468; TYR-478 AND ARG-485.
RX   PubMed=9921913; DOI=10.1007/s004390050901;
RA   Karsten S., Voskoboeva E., Tishkanina S., Pettersson U.,
RA   Krasnopolskaya X., Bondeson M.-L.;
RT   "Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36
RT   unrelated Russian MPS II patients.";
RL   Hum. Genet. 103:732-735(1998).
RN   [30]
RP   VARIANTS MPS2 LEU-86; HIS-88; PRO-88; ILE-118 AND HIS-266.
RX   PubMed=10215411;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU18>3.0.CO;2-G;
RA   Balzano N., Villani G.R.D., Grosso M., Izzo P., di Natale P.;
RT   "Detection of four novel mutations in the iduronate-2-sulfatase
RT   gene.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [31]
RP   VARIANTS MPS2 THR-85; HIS-88; ILE-349 AND VAL-521.
RX   PubMed=9452044;
RA   Gort L., Coll M.J., Chabas A.;
RT   "Mutations in the iduronate-2-sulfatase gene in 12 Spanish patients
RT   with Hunter disease.";
RL   Hum. Mutat. Suppl. 1:S66-S68(1998).
RN   [32]
RP   VARIANTS MPS2 PHE-143; TRP-184; VAL-269 AND HIS-348.
RX   PubMed=10671065;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<433::AID-HUMU12>3.0.CO;2-M;
RA   Karsten S.L., Voskoboeva E., Carlberg B.-M., Kleijer W.J.,
RA   Toennesen T., Pettersson U., Bondeson M.-L.;
RT   "Identification of 9 novel gene mutations in 19 unrelated Hunter
RT   syndrome (Mucopolysaccharidosis type II) patients.";
RL   Hum. Mutat. 12:433-433(1998).
RN   [33]
RP   VARIANTS MPS2 PRO-48; THR-85; LEU-86; PRO-182; SER-196; ASP-225;
RP   MET-227; ASN-308; PRO-314; LEU-333; ARG-337; ILE-349; GLN-468; LEU-468
RP   AND TRP-468.
RX   PubMed=9501270; DOI=10.1023/A:1005363414792;
RA   Isogai K., Sukegawa K., Tomatsu S., Fukao T., Song X.-Q., Yamada Y.,
RA   Fukuda S., Orii T., Kondo N.;
RT   "Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese
RT   patients with mucopolysaccharidosis type II (Hunter disease).";
RL   J. Inherit. Metab. Dis. 21:60-70(1998).
RN   [34]
RP   VARIANTS MPS2 THR-228; ARG-229; LEU-231; GLU-308; ALA-309 AND CYS-313.
RX   PubMed=9762601; DOI=10.1023/A:1005432600871;
RA   Gort L., Chabas A., Coll M.J.;
RT   "Hunter disease in the Spanish population: molecular analysis in 31
RT   families.";
RL   J. Inherit. Metab. Dis. 21:655-661(1998).
RN   [35]
RP   VARIANTS MPS2 PHE-143; LYS-341; TYR-342 AND PHE-491.
RX   PubMed=10220152;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<338::AID-HUMU15>3.0.CO;2-3;
RA   Vallance H.D., Bernard L., Rashed M., Chiu D., Le G., Toone J.,
RA   Applegarth D.A., Coulter-Mackie M.;
RT   "Identification of 6 new mutations in the iduronate sulfatase gene.";
RL   Hum. Mutat. 13:338-338(1999).
RN   [36]
RP   VARIANTS MPS2 ASN-264; PRO-465 AND TRP-468.
RX   PubMed=10447264;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<87::AID-HUMU14>3.0.CO;2-N;
RA   Hartog C., Fryer A., Upadhyaya M.;
RT   "Mutation analysis of iduronate-2-sulphatase gene in 24 patients with
RT   Hunter syndrome: characterisation of 6 novel mutations.";
RL   Hum. Mutat. 14:87-87(1999).
RN   [37]
RP   VARIANTS MPS2 ARG-71; GLU-82; THR-85; CYS-88; ARG-95 DEL; GLN-468;
RP   TRP-468 AND VAL-521.
RX   PubMed=9950361;
RA   Li P., Bellows A.B., Thompson J.N.;
RT   "Molecular basis of iduronate-2-sulphatase gene mutations in patients
RT   with mucopolysaccharidosis type II (Hunter syndrome).";
RL   J. Med. Genet. 36:21-27(1999).
RN   [38]
RP   CHARACTERIZATION OF VARIANTS MPS2 HIS-88; PRO-88; ILE-118 AND GLN-468.
RX   PubMed=10838181; DOI=10.1016/S0925-4439(00)00006-5;
RA   Villani G.R.D., Daniele A., Balzano N., Di Natale P.;
RT   "Expression of five iduronate-2-sulfatase site-directed mutations.";
RL   Biochim. Biophys. Acta 1501:71-80(2000).
RN   [39]
RP   VARIANT MPS2 PRO-41, AND CHARACTERIZATION OF VARIANT MPS2 PRO-41.
RX   PubMed=11015461; DOI=10.1136/jmg.37.10.e29;
RA   Cudry S., Tigaud I., Froissart R., Bonnet V., Maire I., Bozon D.;
RT   "MPS II in females: molecular basis of two different cases.";
RL   J. Med. Genet. 37:E29-E29(2000).
RN   [40]
RP   VARIANTS MPS2 SER-117 DEL; ILE-265 AND THR-347, AND CHARACTERIZATION
RP   OF VARIANTS MPS2 SER-117 DEL; ILE-265 AND THR-347.
RX   PubMed=11731225; DOI=10.1016/S0925-4439(01)00075-8;
RA   Bonuccelli G., Di Natale P., Corsolini F., Villani G., Regis S.,
RA   Filocamo M.;
RT   "The effect of four mutations on the expression of iduronate-2-
RT   sulfatase in mucopolysaccharidosis type II.";
RL   Biochim. Biophys. Acta 1537:233-238(2001).
RN   [41]
RP   VARIANTS MPS2 CYS-88; THR-95; ILE-181; ARG-422; LEU-467; GLN-468 AND
RP   TRP-468.
RX   PubMed=11683780; DOI=10.1034/j.1399-0004.2001.600412.x;
RA   Moreira da Silva I., Froissart R., Marques dos Santos H., Caseiro C.,
RA   Maire I., Bozon D.;
RT   "Molecular basis of mucopolysaccharidosis type II in Portugal:
RT   identification of four novel mutations.";
RL   Clin. Genet. 60:316-318(2001).
RN   [42]
RP   VARIANT MPS2 488-ILE-ALA-489, AND CHARACTERIZATION OF VARIANT MPS2
RP   488-ILE-ALA-489.
RX   PubMed=12794697; DOI=10.1002/ajmg.a.10215;
RA   Ricci V., Filocamo M., Regis S., Corsolini F., Stroppiano M.,
RA   Di Duca M., Gatti R.;
RT   "Expression studies of two novel in CIS-mutations identified in an
RT   intermediate case of Hunter syndrome.";
RL   Am. J. Med. Genet. A 120:84-87(2003).
RN   [43]
RP   VARIANTS MPS2 LEU-41 DEL; TYR-117; PRO-259 AND ILE-299.
RX   PubMed=12655569; DOI=10.1002/humu.9128;
RA   Kim C.H., Hwang H.Z., Song S.M., Paik K.H., Kwon E.K., Moon K.B.,
RA   Yoon J.H., Han C.K., Jin D.-K.;
RT   "Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated
RT   Korean Hunter syndrome patients: identification of 13 novel
RT   mutations.";
RL   Hum. Mutat. 21:449-450(2003).
RN   [44]
RP   VARIANTS MPS2 VAL-82 AND VAL-140, AND CHARACTERIZATION OF VARIANTS
RP   MPS2 VAL-82 AND VAL-140.
RX   PubMed=16699754; DOI=10.1007/s00109-006-0057-1;
RA   Lualdi S., Pittis M.G., Regis S., Parini R., Allegri A.E., Furlan F.,
RA   Bembi B., Filocamo M.;
RT   "Multiple cryptic splice sites can be activated by IDS point mutations
RT   generating misspliced transcripts.";
RL   J. Mol. Med. 84:692-700(2006).
CC   -!- FUNCTION: Required for the lysosomal degradation of heparan
CC       sulfate and dermatan sulfate.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of the 2-sulfate groups of the L-
CC       iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and
CC       heparin.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 1 Ca(2+) ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Liver iduronate 2-sulfatase is composed of two major
CC       forms (A and B) which contain both a 42 kDa and a 14 kDa
CC       polypeptides.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=P22304-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P22304-2; Sequence=VSP_006301, VSP_006302;
CC       Name=3;
CC         IsoId=P22304-3; Sequence=VSP_039116, VSP_039117;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Liver, kidney, lung, and placenta.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. {ECO:0000250}.
CC   -!- DISEASE: Mucopolysaccharidosis 2 (MPS2) [MIM:309900]: An X-linked
CC       lysosomal storage disease characterized by intracellular
CC       accumulation of heparan sulfate and dermatan sulfate and their
CC       excretion in urine. Most children with MPS2 have a severe form
CC       with early somatic abnormalities including skeletal deformities,
CC       hepatosplenomegaly, and progressive cardiopulmonary deterioration.
CC       A prominent feature is neurological damage that presents as
CC       developmental delay and hyperactivity but progresses to mental
CC       retardation and dementia. They die before 15 years of age, usually
CC       as a result of obstructive airway disease or cardiac failure. In
CC       contrast, those with a mild form of MPS2 may survive into
CC       adulthood, with attenuated somatic complications and often without
CC       mental retardation. {ECO:0000269|PubMed:10215411,
CC       ECO:0000269|PubMed:10220152, ECO:0000269|PubMed:10447264,
CC       ECO:0000269|PubMed:10671065, ECO:0000269|PubMed:10838181,
CC       ECO:0000269|PubMed:11015461, ECO:0000269|PubMed:11683780,
CC       ECO:0000269|PubMed:11731225, ECO:0000269|PubMed:12655569,
CC       ECO:0000269|PubMed:12794697, ECO:0000269|PubMed:1284597,
CC       ECO:0000269|PubMed:1303211, ECO:0000269|PubMed:16699754,
CC       ECO:0000269|PubMed:7581397, ECO:0000269|PubMed:7599640,
CC       ECO:0000269|PubMed:7728156, ECO:0000269|PubMed:7866405,
CC       ECO:0000269|PubMed:7887413, ECO:0000269|PubMed:7981716,
CC       ECO:0000269|PubMed:8281149, ECO:0000269|PubMed:8566953,
CC       ECO:0000269|PubMed:8664909, ECO:0000269|PubMed:8830188,
CC       ECO:0000269|PubMed:8940265, ECO:0000269|PubMed:9222763,
CC       ECO:0000269|PubMed:9266380, ECO:0000269|PubMed:9375851,
CC       ECO:0000269|PubMed:9452044, ECO:0000269|PubMed:9501270,
CC       ECO:0000269|PubMed:9660053, ECO:0000269|PubMed:9762601,
CC       ECO:0000269|PubMed:9875019, ECO:0000269|PubMed:9921913,
CC       ECO:0000269|PubMed:9950361}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58342; AAA63197.1; -; mRNA.
DR   EMBL; L13329; AAA16877.1; -; Genomic_DNA.
DR   EMBL; L13321; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13322; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13323; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13324; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13325; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13326; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13327; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13328; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L04586; AAA59192.1; -; Genomic_DNA.
DR   EMBL; L04578; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04579; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04580; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04581; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04583; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04582; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04584; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04585; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L40586; AAA92014.1; -; mRNA.
DR   EMBL; AC233288; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471171; EAW61282.1; -; Genomic_DNA.
DR   EMBL; CH471171; EAW61281.1; -; Genomic_DNA.
DR   EMBL; CH471171; EAW61283.1; -; Genomic_DNA.
DR   EMBL; BC006170; AAH06170.1; -; mRNA.
DR   EMBL; AF011889; AAC77828.1; -; Genomic_DNA.
DR   CCDS; CCDS14685.1; -. [P22304-1]
DR   CCDS; CCDS14686.1; -. [P22304-2]
DR   PIR; A47535; KJHUID.
DR   RefSeq; NP_000193.1; NM_000202.7. [P22304-1]
DR   RefSeq; NP_001160022.1; NM_001166550.3.
DR   RefSeq; NP_006114.1; NM_006123.4. [P22304-2]
DR   UniGene; Hs.460960; -.
DR   UniGene; Hs.6795; -.
DR   PDB; 5FQL; X-ray; 2.30 A; A=26-550.
DR   PDBsum; 5FQL; -.
DR   ProteinModelPortal; P22304; -.
DR   SMR; P22304; -.
DR   BioGrid; 109649; 41.
DR   IntAct; P22304; 2.
DR   MINT; MINT-4722325; -.
DR   STRING; 9606.ENSP00000339801; -.
DR   Allergome; 9623; Hom s Idursulfase.
DR   iPTMnet; P22304; -.
DR   PhosphoSitePlus; P22304; -.
DR   BioMuta; IDS; -.
DR   DMDM; 124174; -.
DR   EPD; P22304; -.
DR   MaxQB; P22304; -.
DR   PaxDb; P22304; -.
DR   PeptideAtlas; P22304; -.
DR   PRIDE; P22304; -.
DR   TopDownProteomics; P22304-3; -. [P22304-3]
DR   Ensembl; ENST00000340855; ENSP00000339801; ENSG00000010404. [P22304-1]
DR   Ensembl; ENST00000370441; ENSP00000359470; ENSG00000010404. [P22304-2]
DR   Ensembl; ENST00000466323; ENSP00000418264; ENSG00000010404. [P22304-3]
DR   GeneID; 3423; -.
DR   KEGG; hsa:3423; -.
DR   UCSC; uc011mxe.3; human. [P22304-1]
DR   CTD; 3423; -.
DR   DisGeNET; 3423; -.
DR   GeneCards; IDS; -.
DR   HGNC; HGNC:5389; IDS.
DR   MalaCards; IDS; -.
DR   MIM; 300823; gene.
DR   MIM; 309900; phenotype.
DR   neXtProt; NX_P22304; -.
DR   OpenTargets; ENSG00000010404; -.
DR   Orphanet; 217093; Mucopolysaccharidosis type 2, attenuated form.
DR   Orphanet; 217085; Mucopolysaccharidosis type 2, severe form.
DR   PharmGKB; PA29636; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00730000110906; -.
DR   HOGENOM; HOG000014304; -.
DR   HOVERGEN; HBG006120; -.
DR   InParanoid; P22304; -.
DR   KO; K01136; -.
DR   OMA; DHNMYND; -.
DR   OrthoDB; EOG091G0B5B; -.
DR   PhylomeDB; P22304; -.
DR   TreeFam; TF323156; -.
DR   BioCyc; MetaCyc:HS00286-MONOMER; -.
DR   BRENDA; 3.1.6.13; 2681.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   SABIO-RK; P22304; -.
DR   ChiTaRS; IDS; human.
DR   GeneWiki; Iduronate-2-sulfatase; -.
DR   GenomeRNAi; 3423; -.
DR   PMAP-CutDB; P22304; -.
DR   PRO; PR:P22304; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000010404; -.
DR   CleanEx; HS_IDS; -.
DR   ExpressionAtlas; P22304; baseline and differential.
DR   Genevisible; P22304; HS.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0004423; F:iduronate-2-sulfatase activity; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030207; P:chondroitin sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 2.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein; Hydrolase;
KW   Lysosome; Metal-binding; Mucopolysaccharidosis; Reference proteome;
KW   Signal; Zymogen.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26     33       {ECO:0000269|PubMed:2122463}.
FT                                /FTId=PRO_0000033428.
FT   CHAIN        34    455       Iduronate 2-sulfatase 42 kDa chain.
FT                                /FTId=PRO_0000033429.
FT   CHAIN       456    550       Iduronate 2-sulfatase 14 kDa chain.
FT                                /FTId=PRO_0000033430.
FT   METAL        45     45       Calcium. {ECO:0000250}.
FT   METAL        46     46       Calcium. {ECO:0000250}.
FT   METAL        84     84       Calcium; via 3-oxoalanine. {ECO:0000250}.
FT   METAL       334    334       Calcium. {ECO:0000250}.
FT   METAL       335    335       Calcium. {ECO:0000250}.
FT   MOD_RES      84     84       3-oxoalanine (Cys). {ECO:0000250}.
FT   CARBOHYD    115    115       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    144    144       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    246    246       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    513    513       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    537    537       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     294    312       RKIRQSYFASVSYLDTQVG -> EDQSSTGFRLKTSSTRKY
FT                                K (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039116.
FT   VAR_SEQ     313    550       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039117.
FT   VAR_SEQ     337    343       WALGEHG -> FLMRTNT (in isoform 2).
FT                                {ECO:0000303|PubMed:8530090}.
FT                                /FTId=VSP_006301.
FT   VAR_SEQ     344    550       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8530090}.
FT                                /FTId=VSP_006302.
FT   VARIANT      41     41       L -> P (in MPS2; mild form; increase in
FT                                enzyme activity observed in transfected
FT                                cells). {ECO:0000269|PubMed:11015461}.
FT                                /FTId=VAR_026915.
FT   VARIANT      41     41       Missing (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026914.
FT   VARIANT      45     45       D -> N (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007313.
FT   VARIANT      48     48       R -> P (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007314.
FT   VARIANT      54     54       Y -> D (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007315.
FT   VARIANT      63     63       N -> D (in MPS2; mild/intermediate form;
FT                                dbSNP:rs193302909).
FT                                {ECO:0000269|PubMed:8664909,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9222763,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007316.
FT   VARIANT      68     68       A -> E (in MPS2; severe).
FT                                {ECO:0000269|PubMed:7981716}.
FT                                /FTId=VAR_007317.
FT   VARIANT      71     71       S -> N (in MPS2; mild form;
FT                                dbSNP:rs113993954).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026916.
FT   VARIANT      71     71       S -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_008998.
FT   VARIANT      73     73       L -> F (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026917.
FT   VARIANT      79     79       A -> E (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007318.
FT   VARIANT      82     82       A -> E (in MPS2).
FT                                {ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_008999.
FT   VARIANT      82     82       A -> V (in MPS2; no significant enzyme
FT                                activity). {ECO:0000269|PubMed:16699754}.
FT                                /FTId=VAR_026918.
FT   VARIANT      85     85       A -> S (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026919.
FT   VARIANT      85     85       A -> T (in MPS2; mild to severe forms;
FT                                dbSNP:rs113993949).
FT                                {ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007319.
FT   VARIANT      86     86       P -> L (in MPS2; intermediate to severe
FT                                forms). {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:7728156,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_007320.
FT   VARIANT      86     86       P -> Q (in MPS2).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007321.
FT   VARIANT      86     86       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8281149,
FT                                ECO:0000269|PubMed:8664909}.
FT                                /FTId=VAR_007322.
FT   VARIANT      87     87       S -> N (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007323.
FT   VARIANT      88     88       R -> C (in MPS2; severe form;
FT                                dbSNP:rs398123249).
FT                                {ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9921913,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007324.
FT   VARIANT      88     88       R -> G (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026920.
FT   VARIANT      88     88       R -> H (in MPS2; intermediate/severe
FT                                form; higher affinity for the artificial
FT                                substrate; poor transport to lysosomes).
FT                                {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:10838181,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007325.
FT   VARIANT      88     88       R -> L (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007326.
FT   VARIANT      88     88       R -> P (in MPS2; severe form; total
FT                                absence of residual activity; poor
FT                                transport to lysosomes).
FT                                {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:10838181}.
FT                                /FTId=VAR_007327.
FT   VARIANT      89     89       V -> F (in MPS2).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026921.
FT   VARIANT      92     92       L -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007328.
FT   VARIANT      94     94       G -> D (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007329.
FT   VARIANT      95     95       R -> G (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8664909}.
FT                                /FTId=VAR_026922.
FT   VARIANT      95     95       R -> T (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:11683780}.
FT                                /FTId=VAR_026923.
FT   VARIANT      95     95       Missing (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_009000.
FT   VARIANT     102    102       L -> R (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007330.
FT   VARIANT     108    108       Y -> C (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007331.
FT   VARIANT     108    108       Y -> S (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026924.
FT   VARIANT     115    115       N -> Y (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007332.
FT   VARIANT     117    117       S -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026926.
FT   VARIANT     117    117       Missing (in MPS2; severe form;
FT                                deleterious mutation; results in an
FT                                inactive enzyme).
FT                                {ECO:0000269|PubMed:11731225,
FT                                ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026925.
FT   VARIANT     118    118       T -> I (in MPS2; mild to severe forms;
FT                                greatly reduced activity; poor transport
FT                                to lysosomes).
FT                                {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:10838181,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_007333.
FT   VARIANT     118    118       Missing (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026927.
FT   VARIANT     120    120       P -> H (in MPS2; mild form;
FT                                dbSNP:rs193302911).
FT                                /FTId=VAR_007334.
FT   VARIANT     120    120       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007335.
FT   VARIANT     121    121       Q -> H (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026928.
FT   VARIANT     121    121       Q -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026929.
FT   VARIANT     125    125       E -> V (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007336.
FT   VARIANT     132    132       S -> W (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7887413,
FT                                ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_007337.
FT   VARIANT     134    134       G -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007338.
FT   VARIANT     135    135       K -> N (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007339.
FT   VARIANT     135    135       K -> R (in MPS2; intermediate form;
FT                                dbSNP:rs28937311).
FT                                {ECO:0000269|PubMed:1303211}.
FT                                /FTId=VAR_007340.
FT   VARIANT     138    138       H -> D (in MPS2; mild/intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026930.
FT   VARIANT     140    140       G -> V (in MPS2; no significant enzyme
FT                                activity). {ECO:0000269|PubMed:16699754}.
FT                                /FTId=VAR_026931.
FT   VARIANT     143    143       S -> F (in MPS2).
FT                                {ECO:0000269|PubMed:10220152,
FT                                ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007341.
FT   VARIANT     148    148       D -> H (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026932.
FT   VARIANT     159    159       H -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007342.
FT   VARIANT     159    159       Missing (in MPS2; intermediate form).
FT                                /FTId=VAR_007343.
FT   VARIANT     160    160       P -> R (in MPS2; dbSNP:rs104894856).
FT                                /FTId=VAR_007344.
FT   VARIANT     181    181       N -> I (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:11683780}.
FT                                /FTId=VAR_026933.
FT   VARIANT     182    182       L -> P (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026934.
FT   VARIANT     184    184       C -> F (in MPS2; mild/intermediate form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007345.
FT   VARIANT     184    184       C -> W (in MPS2).
FT                                {ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007346.
FT   VARIANT     196    196       L -> S (in MPS2; mild/intermediate form;
FT                                dbSNP:rs398123250).
FT                                {ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007347.
FT   VARIANT     198    198       D -> G (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007348.
FT   VARIANT     205    205       A -> P (in MPS2; intermediate form;
FT                                dbSNP:rs864622779).
FT                                {ECO:0000269|PubMed:8664909}.
FT                                /FTId=VAR_026935.
FT   VARIANT     221    221       L -> P (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007349.
FT   VARIANT     224    224       G -> E (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007350.
FT   VARIANT     225    225       Y -> D (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007351.
FT   VARIANT     227    227       K -> M (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026936.
FT   VARIANT     227    227       K -> Q (in MPS2; severe form).
FT                                /FTId=VAR_007352.
FT   VARIANT     228    228       P -> L (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007353.
FT   VARIANT     228    228       P -> T (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026937.
FT   VARIANT     229    229       H -> R (in MPS2; intermediate/severe
FT                                form; dbSNP:rs193302905).
FT                                {ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026938.
FT   VARIANT     229    229       H -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007354.
FT   VARIANT     231    231       P -> L (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026939.
FT   VARIANT     252    252       D -> N (in MPS2; dbSNP:rs146458524).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007355.
FT   VARIANT     259    259       L -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026940.
FT   VARIANT     264    264       Y -> N (in MPS2).
FT                                {ECO:0000269|PubMed:10447264}.
FT                                /FTId=VAR_009001.
FT   VARIANT     265    265       N -> I (in MPS2; intermediate form;
FT                                deleterious mutation; residual activity
FT                                of 7.5% of the wild-type).
FT                                {ECO:0000269|PubMed:11731225}.
FT                                /FTId=VAR_026941.
FT   VARIANT     266    266       P -> H (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:10215411}.
FT                                /FTId=VAR_007356.
FT   VARIANT     266    266       P -> R (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007357.
FT   VARIANT     269    269       D -> V (in MPS2).
FT                                {ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007358.
FT   VARIANT     293    293       Q -> H (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7981716}.
FT                                /FTId=VAR_007359.
FT   VARIANT     299    299       S -> I (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026942.
FT   VARIANT     308    308       D -> E (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026943.
FT   VARIANT     308    308       D -> N (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026944.
FT   VARIANT     309    309       T -> A (in MPS2; severe form;
FT                                dbSNP:rs145807417).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026945.
FT   VARIANT     313    313       R -> C (in MPS2; unknown pathological
FT                                significance; dbSNP:rs201048643).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026946.
FT   VARIANT     314    314       L -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026947.
FT   VARIANT     333    333       S -> L (in MPS2; severe form;
FT                                dbSNP:rs104894853).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:8566953,
FT                                ECO:0000269|PubMed:8830188,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007360.
FT   VARIANT     334    334       D -> G (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8830188}.
FT                                /FTId=VAR_009002.
FT   VARIANT     334    334       D -> N (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026948.
FT   VARIANT     335    335       H -> R (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026949.
FT   VARIANT     336    336       G -> E (in MPS2; severe from).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026950.
FT   VARIANT     336    336       G -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026951.
FT   VARIANT     337    337       W -> R (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007361.
FT   VARIANT     339    339       L -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026952.
FT   VARIANT     340    340       G -> D (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007362.
FT   VARIANT     341    341       E -> K (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:10220152,
FT                                ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_008134.
FT   VARIANT     342    342       H -> Y (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:10220152}.
FT                                /FTId=VAR_008135.
FT   VARIANT     345    345       W -> C (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007363.
FT   VARIANT     346    346       A -> D (in MPS2; mild/severe form).
FT                                {ECO:0000269|PubMed:8566953}.
FT                                /FTId=VAR_007364.
FT   VARIANT     346    346       A -> V (in MPS2; mild/severe form).
FT                                {ECO:0000269|PubMed:7599640}.
FT                                /FTId=VAR_007365.
FT   VARIANT     347    347       K -> I (in MPS2).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007366.
FT   VARIANT     347    347       K -> Q (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026953.
FT   VARIANT     347    347       K -> T (in MPS2; severe form; deleterious
FT                                mutation confirmed).
FT                                {ECO:0000269|PubMed:11731225,
FT                                ECO:0000269|PubMed:9222763}.
FT                                /FTId=VAR_007367.
FT   VARIANT     348    348       Y -> H (in MPS2).
FT                                {ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007368.
FT   VARIANT     349    349       S -> I (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007369.
FT   VARIANT     358    358       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007370.
FT   VARIANT     403    403       L -> R (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_007371.
FT   VARIANT     410    410       L -> P (in MPS2).
FT                                {ECO:0000269|PubMed:7866405}.
FT                                /FTId=VAR_026954.
FT   VARIANT     422    422       C -> G (in MPS2; mild form;
FT                                dbSNP:rs28937310).
FT                                {ECO:0000269|PubMed:1303211,
FT                                ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007372.
FT   VARIANT     422    422       C -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:11683780}.
FT                                /FTId=VAR_026955.
FT   VARIANT     432    432       C -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007373.
FT   VARIANT     434    434       E -> K (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007374.
FT   VARIANT     465    465       Q -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:10447264}.
FT                                /FTId=VAR_009003.
FT   VARIANT     467    467       P -> L (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026956.
FT   VARIANT     468    468       R -> G (in MPS2; mild to severe forms).
FT                                /FTId=VAR_007375.
FT   VARIANT     468    468       R -> L (in MPS2; mild to severe forms;
FT                                dbSNP:rs113993946).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:9222763,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007376.
FT   VARIANT     468    468       R -> Q (in MPS2; severe/intermediate
FT                                form; greatly reduced activity; poor
FT                                transport to lysosomes;
FT                                dbSNP:rs113993946).
FT                                {ECO:0000269|PubMed:10838181,
FT                                ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:8664909,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9222763,
FT                                ECO:0000269|PubMed:9266380,
FT                                ECO:0000269|PubMed:9375851,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9921913,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007377.
FT   VARIANT     468    468       R -> W (in MPS2; mild to severe forms;
FT                                dbSNP:rs199422231).
FT                                {ECO:0000269|PubMed:10447264,
FT                                ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:1284597,
FT                                ECO:0000269|PubMed:7728156,
FT                                ECO:0000269|PubMed:8664909,
FT                                ECO:0000269|PubMed:9266380,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007378.
FT   VARIANT     469    469       P -> H (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007379.
FT   VARIANT     478    478       D -> G (in MPS2; mild form;
FT                                dbSNP:rs864622773).
FT                                {ECO:0000269|PubMed:7981716}.
FT                                /FTId=VAR_007380.
FT   VARIANT     478    478       D -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007381.
FT   VARIANT     480    480       P -> L (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026957.
FT   VARIANT     480    480       P -> Q (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026958.
FT   VARIANT     480    480       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026959.
FT   VARIANT     485    485       I -> K (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007382.
FT   VARIANT     485    485       I -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7981716,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007383.
FT   VARIANT     488    489       MG -> IA (in MPS2; intermediate form;
FT                                mutation A-489 confirmed as causative of
FT                                MPS2).
FT                                /FTId=VAR_026960.
FT   VARIANT     490    490       Y -> S (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026961.
FT   VARIANT     491    491       S -> F (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:10220152}.
FT                                /FTId=VAR_008136.
FT   VARIANT     502    502       W -> C (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007384.
FT   VARIANT     502    502       W -> S (in MPS2; dbSNP:rs199422228).
FT                                /FTId=VAR_007385.
FT   VARIANT     521    521       E -> K (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026962.
FT   VARIANT     521    521       E -> V (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380,
FT                                ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007386.
FT   VARIANT     523    523       Y -> C (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007387.
FT   STRAND       38     44       {ECO:0000244|PDB:5FQL}.
FT   HELIX        52     54       {ECO:0000244|PDB:5FQL}.
FT   STRAND       57     59       {ECO:0000244|PDB:5FQL}.
FT   HELIX        62     69       {ECO:0000244|PDB:5FQL}.
FT   STRAND       71     78       {ECO:0000244|PDB:5FQL}.
FT   STRAND       80     83       {ECO:0000244|PDB:5FQL}.
FT   HELIX        84     93       {ECO:0000244|PDB:5FQL}.
FT   HELIX        97    100       {ECO:0000244|PDB:5FQL}.
FT   STRAND      103    106       {ECO:0000244|PDB:5FQL}.
FT   HELIX       109    112       {ECO:0000244|PDB:5FQL}.
FT   HELIX       119    125       {ECO:0000244|PDB:5FQL}.
FT   STRAND      129    137       {ECO:0000244|PDB:5FQL}.
FT   HELIX       141    143       {ECO:0000244|PDB:5FQL}.
FT   TURN        144    147       {ECO:0000244|PDB:5FQL}.
FT   TURN        149    151       {ECO:0000244|PDB:5FQL}.
FT   HELIX       161    165       {ECO:0000244|PDB:5FQL}.
FT   STRAND      182    186       {ECO:0000244|PDB:5FQL}.
FT   HELIX       188    190       {ECO:0000244|PDB:5FQL}.
FT   HELIX       192    194       {ECO:0000244|PDB:5FQL}.
FT   HELIX       197    212       {ECO:0000244|PDB:5FQL}.
FT   STRAND      219    225       {ECO:0000244|PDB:5FQL}.
FT   STRAND      229    235       {ECO:0000244|PDB:5FQL}.
FT   HELIX       236    241       {ECO:0000244|PDB:5FQL}.
FT   HELIX       244    246       {ECO:0000244|PDB:5FQL}.
FT   HELIX       261    263       {ECO:0000244|PDB:5FQL}.
FT   HELIX       270    272       {ECO:0000244|PDB:5FQL}.
FT   HELIX       274    277       {ECO:0000244|PDB:5FQL}.
FT   TURN        283    285       {ECO:0000244|PDB:5FQL}.
FT   HELIX       290    320       {ECO:0000244|PDB:5FQL}.
FT   TURN        324    326       {ECO:0000244|PDB:5FQL}.
FT   STRAND      327    334       {ECO:0000244|PDB:5FQL}.
FT   STRAND      338    340       {ECO:0000244|PDB:5FQL}.
FT   HELIX       341    343       {ECO:0000244|PDB:5FQL}.
FT   STRAND      345    349       {ECO:0000244|PDB:5FQL}.
FT   HELIX       352    355       {ECO:0000244|PDB:5FQL}.
FT   STRAND      359    362       {ECO:0000244|PDB:5FQL}.
FT   TURN        364    366       {ECO:0000244|PDB:5FQL}.
FT   STRAND      395    402       {ECO:0000244|PDB:5FQL}.
FT   HELIX       403    405       {ECO:0000244|PDB:5FQL}.
FT   HELIX       406    413       {ECO:0000244|PDB:5FQL}.
FT   STRAND      433    435       {ECO:0000244|PDB:5FQL}.
FT   HELIX       439    442       {ECO:0000244|PDB:5FQL}.
FT   HELIX       457    460       {ECO:0000244|PDB:5FQL}.
FT   STRAND      462    469       {ECO:0000244|PDB:5FQL}.
FT   STRAND      477    479       {ECO:0000244|PDB:5FQL}.
FT   HELIX       482    484       {ECO:0000244|PDB:5FQL}.
FT   STRAND      487    493       {ECO:0000244|PDB:5FQL}.
FT   STRAND      495    506       {ECO:0000244|PDB:5FQL}.
FT   TURN        507    510       {ECO:0000244|PDB:5FQL}.
FT   STRAND      511    524       {ECO:0000244|PDB:5FQL}.
FT   TURN        525    527       {ECO:0000244|PDB:5FQL}.
FT   HELIX       542    548       {ECO:0000244|PDB:5FQL}.
SQ   SEQUENCE   550 AA;  61873 MW;  EA1B713417280413 CRC64;
     MPPPRTGRGL LWLGLVLSSV CVALGSETQA NSTTDALNVL LIIVDDLRPS LGCYGDKLVR
     SPNIDQLASH SLLFQNAFAQ QAVCAPSRVS FLTGRRPDTT RLYDFNSYWR VHAGNFSTIP
     QYFKENGYVT MSVGKVFHPG ISSNHTDDSP YSWSFPPYHP SSEKYENTKT CRGPDGELHA
     NLLCPVDVLD VPEGTLPDKQ STEQAIQLLE KMKTSASPFF LAVGYHKPHI PFRYPKEFQK
     LYPLENITLA PDPEVPDGLP PVAYNPWMDI RQREDVQALN ISVPYGPIPV DFQRKIRQSY
     FASVSYLDTQ VGRLLSALDD LQLANSTIIA FTSDHGWALG EHGEWAKYSN FDVATHVPLI
     FYVPGRTASL PEAGEKLFPY LDPFDSASQL MEPGRQSMDL VELVSLFPTL AGLAGLQVPP
     RCPVPSFHVE LCREGKNLLK HFRFRDLEED PYLPGNPREL IAYSQYPRPS DIPQWNSDKP
     SLKDIKIMGY SIRTIDYRYT VWVGFNPDEF LANFSDIHAG ELYFVDSDPL QDHNMYNDSQ
     GGDLFQLLMP
//
